Study Of Avb-S6-500 In Combination With Cabozantinib Versus

Recruiting

18 years - 99 years

All

Phase 2

25 participants needed

1 Location

Brief description of study

This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Clear Cell Renal Cell Carcinoma
Age: 18 years - 99 years
Gender: All

Male or Female 18 years of age or older Clear Cell Renal Cell Carcinoma

Updated on 04 Aug 2024. Study ID: 849104

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study Of Avb-S6-500 In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Advanced Clear Cell Renal Cell Carcinoma Who Have Received Front-Line Treatment

Brief description of study

Eligibility of study

Find a site

Interested in the study